Viridian Therapeutics is advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. In our lead programs, we are developing multiple product candidates that target the insulin-like growth factor-1 receptor (IGF-1R) to treat patients who suffer from thyroid eye disease (TED), a debilitating auto-immune disease.
Learn more about Viridian and our programs in our corporate presentation.
Recent Press Releases
- Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration
- Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)